

Reappraising the long-term course and outcome of psychotic disorders: the AESOP-10 study

C. Morgan^{1,2*}, J. Lappin^{2,3}, M. Heslin⁴, K. Donoghue⁵, B. Lomas⁶, U. Reininghaus¹, A. Onyejiaka¹, T. Croudace⁷, P. B. Jones⁸, R. M. Murray^{2,3}, P. Fearon⁹, G. A. Doody⁶ and P. Dazzan^{2,3}

¹Centre for Epidemiology and Public Health, Health Service and Population Research Department, Institute of Psychiatry, King's College London, UK

²National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, UK

³Department of Psychosis Studies, Institute of Psychiatry, King's College London, UK

⁴Centre for Economics of Mental and Physical Health, Health Service and Population Research Department, Institute of Psychiatry, King's College London, UK

⁵Addictions Department, Institute of Psychiatry, King's College London, UK

⁶Division of Psychiatry, University of Nottingham, UK

⁷Department of Health Sciences, University of York, UK

⁸Department of Psychiatry, University of Cambridge, UK

⁹Department of Psychiatry, Trinity College, Dublin, Ireland

Background. Studies of the long-term course and outcome of psychoses tend to focus on cohorts of prevalent cases. Such studies bias samples towards those with poor outcomes, which may distort our understanding of prognosis. Long-term follow-up studies of epidemiologically robust first-episode samples are rare.

Method. AESOP-10 is a 10-year follow-up study of 557 individuals with a first episode of psychosis initially identified in two areas in the UK (South East London and Nottingham). Detailed information was collated on course and outcome in three domains (clinical, social and service use) from case records, informants and follow-up interviews.

Results. At follow-up, of 532 incident cases identified, at baseline 37 (7%) had died, 29 (6%) had emigrated and eight (2%) were excluded. Of the remaining 458, 412 (90%) were traced and some information on follow-up was collated for 387 (85%). Most cases (265, 77%) experienced at least one period of sustained remission; at follow-up, 141 (46%) had been symptom free for at least 2 years. A majority (208, 72%) of cases had been employed for less than 25% of the follow-up period. The median number of hospital admissions, including at first presentation, was 2 [interquartile range (IQR) 1–4]; a majority (299, 88%) were admitted at least once and a minority (21, 6%) had 10 or more admissions. Overall, outcomes were worse for those with a non-affective diagnosis, for men and for those from South East London.

Conclusions. Sustained periods of symptom remission are usual following first presentation to mental health services for psychosis, including for those with a non-affective disorder; almost half recover.

Received 16 August 2013; Revised 10 January 2013; Accepted 17 January 2014; First published online 26 February 2014

Key words: AESOP-10 study, course and outcome, psychotic disorders, recovery, remission.

Introduction

Studies of the long-term course and outcome of psychosis have tended to focus on those with a diagnosis of schizophrenia (or non-affective psychosis) and to follow cohorts of prevalent cases (Hegarty *et al.* 1994). Such designs bias samples towards those with poor outcomes (Cohen & Cohen, 1984; van Os *et al.* 1997) and distort our understanding of long-term prognosis.

Studies of unselected samples of incident cases of all psychoses provide the optimum basis for investigating the variability and determinants of course and outcome over the long term. With the introduction of specialist services for those with a first episode of psychosis in many countries, a new wave of cohorts has been established. Many of these have already reported on short- (1–2 years) to medium- (5 years) term outcomes (e.g. Craig *et al.* 2004; Larsen *et al.* 2006, 2011; Malla *et al.* 2008; Gafoor *et al.* 2010; Nordentoft *et al.* 2010; Norman *et al.* 2012). However, only a few have reported longer-term outcomes (e.g. Hegelstad *et al.* 2012). There are, moreover, still limitations to these cohorts and their capacity to provide generalizable information about the long-term trajectories of psychosis. Some comprise individuals recruited

* Address for correspondence: Dr C. Morgan, Centre for Epidemiology and Public Health, Health Service and Population Research Department, Institute of Psychiatry, King's College London, Box P063, De Crespigny Park, London SE5 8AF, UK.
(Email: craig.morgan@kcl.ac.uk)

into clinical trials; the extent to which those who take part are representative of those with a first episode is unclear. In addition, many restrict inclusion to those with non-affective psychoses or to narrow age groups (e.g. 16 to 35 years). Studies of unselected samples of incident cases with all psychotic disorders remain rare.

Long-term follow-up studies of first-episode psychosis

To gain some traction on existing findings from long-term (defined here pragmatically as 8 years or more to enhance comparability with our data) follow-up studies of first-episode psychosis, we conducted a review of studies since 1980 drawing, in from prior systematic reviews (Hegarty *et al.* 1994; van Os *et al.* 1997; Menezes *et al.* 2006; Jaaskelainen *et al.* 2008).

Supplementary Table S1 summarizes the methods and main findings on course and outcome from the 13 studies (16 papers) that we identified. There was considerable heterogeneity in reported outcomes. For example, estimates of proportions in remission or recovered (variously defined) at follow-up ranged from 20% (Ciompi, 1980) to 78% (Thara *et al.* 1994). This variability extended to social outcomes. The proportions in paid work at follow-up, for instance, ranged from 19% (White *et al.* 2009) to around 40% (Harrison *et al.* 2001; Harrison & Mason, 2007). What is perhaps most striking is how methodologically diverse these studies are, with little consistency in inclusion criteria, in length of follow-up, and in definitions and measures of course and outcome. For example, there was notable variation in how remission and recovery were operationalized. In some studies remission was defined as total absence of symptoms (e.g. Thara *et al.* 1994) and in others as symptoms below a certain threshold (e.g. Crumlish *et al.* 2009); the time period for achieving remission also varied from 1 month (e.g. Crumlish *et al.* 2009) to 6 months (e.g. Kurihara *et al.* 2011). There were similar inconsistencies in how recovery, a concept implying more sustained improvement over time, was defined and operationalized. Furthermore, only three studies were of first-episode cases of all psychoses (Harrison *et al.* 2001; Harris *et al.* 2005; Harrison & Mason, 2007; Hill *et al.* 2012). In sum, our knowledge of the long-term course and outcome of psychosis is limited both by the methodological heterogeneity of existing studies and by a paucity of epidemiologically robust studies of first-episode cohorts.

AESOP-10

In this context, the AESOP-10 study, a 10-year follow-up of a large epidemiologically characterized sample

of first-episode cases of all psychoses, has the potential to provide novel insights into the nature and determinants of long-term trajectories and outcomes. In this lead paper from the study, we provide a detailed account of the procedures and methods used in AESOP-10, and report primary findings on course and outcome across three domains: clinical, social and service use (hospital admissions).

Method


AESOP-10 is a follow-up at approximately 10 years of a cohort of 557 individuals with a first episode of psychosis initially identified in the South East London and Nottingham centres of the Aetiology and Ethnicity in Schizophrenia and Other Psychoses (AESOP) study (Kirkbride *et al.* 2006). At baseline, a team of researchers screened all in-patient (daily) and out-patient (weekly) mental health services in the catchment areas to identify eligible cases. The sample of 557 comprises all incident cases identified (532) and additional cases identified on a more *ad-hoc* basis to supplement the brain imaging component of the baseline study (25). In this paper we focus on the 532 incident cases.

Ethics

Full ethical approval for all aspects of the follow-up was provided by the local research ethics committees in South East London and Nottingham. All researchers had substantive or honorary contracts with either the South London and Maudsley National Health Service (NHS) Foundation Trust or the Nottingham Healthcare NHS Trust, the primary participating service providers.

Tracing and recontact procedures

Our procedures for tracing cases were in line with those used in previous long-term follow-up studies (e.g. Harrison *et al.* 2001). At approximately 10 years after inclusion in the baseline study, we sought to trace, recontact and reinterview all cases. When identified and recruited originally, detailed recontact information was collected for all cases. We began by establishing whether cases were currently in contact with mental health services. For those who were, we sought to make contact and invite them to participate through their clinical teams. For those who were not, we sent letters to their last known address inviting them to participate. Non-responders were sent a further letter 2 weeks later and, if necessary, researchers made a maximum of three visits to the address (morning, afternoon and evening) to make initial contact. For those who had moved address, and for whom



Administrative Outcomes

Dead	Abroad	Excluded	No capacity	Re-interviewed	Declined	Traced, no contact	Not traced
37 (7.0%)	29 (5.5%)	8 (1.5%)	4 (0.8%)	219 (41.2%)	168 (31.6%)	21 (4.0%)	46 (8.7%)

Fig. 1. Flow chart documenting how cases were traced and administrative outcomes. ONS, Office for National Statistics, for England and Wales; GRO, General Register Office for Scotland.

we had general practitioner (GP) contact details, we sought to make contact and invite them to participate through their GP (see Fig. 1). All deaths and emigrations up to and including those that occurred on 12 December 2012 were identified by a case-tracing procedure with the Office for National Statistics (ONS) for England and Wales and the General Register Office (GRO) for Scotland using name, sex, date of birth and last known address.

Data at baseline

At baseline, information was collated on clinical presentation and basic sociodemographic characteristics, and assessments were completed with cases on a range of putative biological, psychological and social risk factors (Morgan *et al.* 2006). Baseline ICD-10

and DSM-IV diagnoses were determined, using data collected with the Schedules for Clinical Assessment in Neuropsychiatry (SCAN; WHO, 1992), on the basis of consensus meetings involving one of the principal investigators and other members of the research team.

Data at follow-up

Clinical course and outcome

At follow-up, extensive information was collated across three course and outcome domains (clinical, social and service use) from clinical records and, where possible, from follow-up interviews with cases and treating clinicians using an extended version of the World Health Organization (WHO) Life Chart (Sartorius *et al.* 1996; see also Burns *et al.* 1999;

Harrison *et al.* 2001). The extended version adapted the original Life Chart to include more items on substance use, medication and service contacts and to include a timeline (following Wiersma *et al.* 1998) to document, month by month where possible, presence of psychotic symptoms and contacts with mental health services. In interviews with cases, we used significant anchor dates to orientate subjects and assist recall and, as appropriate, interviews were structured around key events, such as hospital admissions. Using all available information, researchers painstakingly reconstructed case histories over the follow-up period. The primary course and outcome parameters and variables derived from the Life Chart are detailed in Supplementary Table S2.

In addition, information on current symptoms at follow-up (i.e. the preceding month) was collected using the SCAN (WHO, 1992).

Remission

In line with Andreasen *et al.* (2005), we defined remission as absence of overt psychotic symptoms (operationalized as a score of 2 or 3 on Rating Scale 2 in the SCAN; 0=absence, 1=symptom occurred, but fleeting, 2=symptom definitely present, 3=symptom present more or less continuously) for a period of at least 6 months. We defined symptom recovery as sustained remission for at least 2 years.

Consensus ratings and diagnosis

We adopted a consensus approach to Life Chart clinical ratings and lifetime diagnoses. At weekly meetings involving principal investigators, researchers presented detailed summaries of the clinical symptomatology and course and outcome for each case based on information collated from clinical records and interviews with cases and other informants. These formed the bases for consensus ratings of: (a) variables in the Life Chart relating to the occurrence and nature of psychotic episodes and substance use during the follow-up period; and (b) lifetime ICD-10 and DSM-IV diagnoses. A conservative approach was adopted such that positive ratings of, for example, presence or absence of psychotic symptoms were only made if there was definite evidence.

Social

Information on sociodemographic markers of social function and integration across several domains (i.e. housing, employment, relationships, education and social networks) during and at follow-up was collected using the Life Chart. In this paper we present illustrative data on employment and relationship status.

Mental health service use

Information on the nature and types of contacts with specialist mental health services and prescription of and compliance with antipsychotic medication throughout the follow-up was collated using the Life Chart, which was expanded to include a timeline to document, month by month, contacts with services and more detail on each hospital admission and community contact (i.e. dates of admission or contact, mode of contact, source of referral, etc.).

Analysis

We described primary outcomes using frequencies and percentages and means or medians and standard deviations or interquartile ranges (IQRs). Comparisons by sex, baseline diagnosis (non-affective *versus* affective) and study centre were made using χ^2 tests, *t* tests, ANOVAs and rank sum tests and, for time to first remission, Kaplan–Meier survival curves and log rank tests and, for number of admissions, Poisson regression. Analyses were conducted using Stata version 11 (Stata Corporation, USA).

Results

At follow-up, of the 532 incident cases initially identified, 37 (7.0%) had died: a mortality rate of 739/100000 person-years; standardized mortality ratio (SMR) 3.59 (95% CI 2.60–4.96). Twenty-nine (5.5%) had emigrated and eight (1.5%) were excluded on the basis of information not available at baseline. Of the 458 remaining, 412 (90.0%) were traced successfully. Of these, 219 (53.2%) were reinterviewed, four (1.0%) lacked capacity (due to dementia or head trauma) and 189 (45.8%) could not be contacted or declined reinterview (Fig. 1). Those who had died tended to be older and were more likely to be men; those who had emigrated were more likely to be of black African ethnicity and from London; those who were not traceable were more likely to be men and have a diagnosis of a non-affective psychosis (Table 1).

Core analytic sample

After removing those who had died, emigrated or been excluded, useable information on clinical course and outcome across one or more of our three domains was available on 387 (84.5% of 458) cases for at least 8 years of follow-up (our core analytic sample), a combined total of 4141 years of follow-up (mean length of follow-up=10.7 years, s.d.=1.2, range 8.1–13.7).

When we compared cases with some information for at least 8 years with those without, there was no evidence of systematic differences by age, sex,

Table 1. Baseline demographic characteristics and diagnosis by administrative outcome

	Total	Reinterviewed	Declined	Traced, no contact	Untraceable	Abroad	Dead	No capacity	Excluded	<i>F, χ^2; df; p</i>
<i>n</i>	532	219	168	21	46	29	37	4	8	
Sex, <i>n</i> (%)										
Men	308 (57.9)	125 (57.1)	91 (54.2)	9 (42.8)	33 (71.7)	18 (62.1)	26 (70.3)	2 (50.0)	4 (50.0)	9.4; 7; 0.224
Women	224 (42.1)	94 (42.9)	77 (45.8)	12 (57.1)	13 (28.3)	11 (36.7)	11 (29.7)	2 (50.0)	4 (50.0)	
Baseline age (years), mean (s.d.)	30.8 (10.7)	29.8 (9.9)	30.5 (10.5)	29.1 (10.5)	29.2 (9.4)	31.2 (10.1)	36.1 (12.5)	37.5 (15.7)	43.2 (18.1)	4.3; 7; < 0.001
Ethnicity, <i>n</i> (%)										
White British	232 (43.6)	92 (42.0)	74 (44.1)	10 (47.6)	27 (58.7)	3 (10.3)	20 (54.1)	2 (50.0)	4 (50.0)	63.6; 35; 0.002
Other white	37 (7.0)	17 (7.8)	8 (4.8)	1 (4.8)	5 (10.9)	3 (10.3)	2 (5.4)	0 (0.0)	1 (12.5)	
Black Caribbean	140 (26.3)	69 (31.5)	44 (26.2)	3 (14.3)	7 (15.2)	5 (17.2)	8 (21.6)	1 (25.0)	3 (37.5)	
Black African	65 (12.2)	19 (8.7)	22 (13.1)	3 (14.3)	3 (6.5)	13 (44.8)	4 (10.8)	1 (25.0)	0 (0.0)	
Asian	26 (4.9)	10 (4.6)	12 (7.1)	2 (9.5)	0 (0.0)	1 (3.5)	1 (2.7)	0 (0.0)	0 (0.0)	
Other	32 (6.0)	12 (5.5)	8 (4.8)	2 (9.5)	4 (8.7)	4 (13.8)	2 (5.4)	0 (0.0)	0 (0.0)	
Study centre, <i>n</i> (%)										
London	327 (61.5)	155 (70.8)	82 (48.8)	9 (42.9)	26 (56.5)	26 (89.7)	21 (56.8)	4 (100.0)	4 (50.0)	35.9; 7; < 0.001
Nottingham	205 (38.5)	64 (29.2)	86 (51.2)	12 (57.1)	20 (43.5)	3 (10.3)	16 (43.2)	0 (0.0)	4 (50.0)	
Baseline diagnosis, <i>n</i> (%)										
Non-affective psychosis	385 (72.4)	154 (70.3)	119 (70.8)	12 (57.1)	38 (82.6)	21 (72.4)	30 (81.1)	4 (100.0)	7 (87.5)	12.5; 14; 0.567
Manic psychosis	71 (13.4)	32 (14.6)	23 (13.7)	4 (19.1)	3 (6.5)	6 (20.7)	3 (8.1)	0 (0.0)	0 (0.0)	
Depressive psychosis	76 (14.3)	33 (15.1)	26 (14.5)	5 (23.8)	5 (10.9)	2 (6.9)	4 (10.8)	0 (0.0)	1 (12.5)	

s.d., Standard deviation; df, degrees of freedom.

ethnicity, duration of untreated psychosis, baseline employment, baseline diagnosis, mode of initial contact with mental health services or study centre (Supplementary Table S3). There was some evidence that those for whom we did not get some information were more likely to have had an acute onset. When we considered source of information (case reinterview *versus* no case reinterview) among those with data for at least 8 years, the only differences were in relation to length of follow-up (slightly shorter for reinterview group) and study centre (cases in London were more likely to have been reinterviewed) (Supplementary Table S4).

Long-term course and outcome

Clinical

In our core sample, there was marked variability in clinical course (Table 2). Eighty cases (23% of 345, missing 42) did not experience a remission of psychotic symptoms of 6 months or more at any point during the follow-up (i.e. continuous). Of these, symptoms were rated as severe in 23 (29% of 80; 7% of 345) and negative symptoms were a marked feature of the clinical picture in 37 (46% of 80; 11% of 345). At the other end of the spectrum, 43 (13% of 345) had a remission of symptoms within 6 months of first contact and remained symptom free for the duration of the follow-up; a further 69 (20% of 345) did have further episodes after initial remission, but none lasting more than 6 months (i.e. episodic). The remaining cases (153, 44% of 345) formed an intermediate group that had had at least one remission of 6 months or longer and at least one episode of 6 months or longer (i.e. neither continuous nor episodic). In total, 265 (77%) had at least one remission during the follow-up period, with a median time to first remission of 18 weeks (IQR 6–425). At follow-up, 213 (65% of 326, missing 61) were not experiencing psychotic symptoms and 140 (46% of 303 for whom complete data were available, missing 84) had been free of psychotic symptoms for the preceding 2 years or more (i.e. met criteria for symptom recovery). It is notable that, among the 228 cases for whom we had reliable information (75% of 303 with data on recovery), 56% of those who were recovered (57 of 101) had been prescribed antipsychotic medication in the 2 years prior to follow-up, compared with 86% (109 of 127) of those not recovered ($\chi^2=24.6$, $df=1$, $p<0.001$). (Note that all cases were, at some point, prescribed antipsychotic medication.) Across all indicators, those with an initial diagnosis of a non-affective psychosis, men and London cases were more likely to experience a worse clinical course and outcome (Table 2 and Supplementary Fig. S1).

Clinical course types

Combining data on overall course type and clinical status at follow-up (i.e. in episode or not) with information on mode of onset, we were able to categorize cases according to the course types originally specified by Bleuler (1978). Figure 2 illustrates these and presents the frequencies and percentages for our sample (by diagnosis) alongside those reported by Bleuler (1978), Ciompi (1980) and Harrison *et al.* (2001). In all studies, an undulating course (i.e. episodic and neither continuous nor episodic) with good outcome was the most common (percentages in each study range from 35% to 65%); a chronic course with poor outcome was much less common (percentages in each study range from 12% to 32%).

Social

Using employment and relationship status as illustrative indicators of social outcomes, there was strong evidence that the marked social exclusion present among cases at baseline (e.g. 28% of cases employed *versus* 55% of controls; 71% of cases not in a relationship *versus* 39% of controls; Morgan *et al.* 2008) persisted through the follow-up period. For example, only a small minority of cases in our core sample had been in paid work for over 75% of the follow-up period (34 of 290; 12%). A slightly larger proportion had been employed for between 25% and 75% of the follow-up (48; 17%). The overwhelming majority, however, had been employed for less than 25% of the time (208, 72%). These low levels of employment were evident at follow-up, with only 66 (22%) being in paid work 10 years after initial presentation to mental health services. The proportions of the general populations in paid employment around the time of follow-up in each of the areas from which cases were recruited were: 67% in Lambeth, South East London; 62% in Southwark, South East London; and 49% in Nottingham (www.nomisweb.co.uk/census/2011/key_statistics). With regard to relationship status, a majority of cases were single for most of the follow-up (218, 71%) and at follow-up (205, 68%). Unfortunately, comparable data for general populations on relationship status are not available. Those with a baseline diagnosis of non-affective psychosis and London cases were more likely to experience poor outcomes in these domains (Table 3). Furthermore, these findings suggest that social exclusion emerges before or early after onset and persists over the long term. Of those cases in our core follow-up sample who were not employed at baseline, only 15% (34 of 223) were in employment at follow-up. Similarly, of those not in a relationship at baseline, only 16% (33 of 210) were in a relationship at follow-up.

Table 2. *Clinical course and outcome*

	Diagnosis					Sex					Centre					
	Overall	Non-affective (n=277)	Affective (n=110)	F, t, χ^2	df	p	Men (n=215)	Women (n=172)	F, t, χ^2	df	p	London (n=230)	Nottingham (n=157)	F, t, χ^2	df	p
Time to remission (weeks) (n=326)																
Median	17.5	32.0	7.7	4.90	-	<0.001	27.5	11.9	2.81	-	0.005	25.5	12.3	3.14	-	0.002
IQR	5.6–425.4	7.0–495.8	3.4–221.0				6.0–486.6	4.1–95.0				6.1–484.0	3.7–59.4			
Course (n=345), n (%)																
No episodes	43 (12.5)	21 (8.5)	22 (22.5)	41.93	3	<0.001	15 (8.0)	28 (17.8)	14.51	3	0.002	27 (12.6)	16 (12.3)	8.82	3	0.032
Episodic	69 (20.0)	35 (14.2)	34 (34.7)				31 (16.5)	38 (24.2)				36 (16.7)	33 (25.4)			
Neither	153 (44.4)	119 (48.2)	34 (34.7)				89 (47.3)	64 (40.8)				92 (42.8)	61 (46.9)			
Continuous	80 (23.2)	72 (29.2)	8 (8.2)				53 (28.2)	27 (17.2)				60 (27.9)	20 (15.4)			
Recovered (symptoms) (n=303), n (%)																
Yes	140 (46.2)	87 (39.7)	53 (63.1)	13.34	1	<0.001	67 (41.4)	73 (51.8)	3.29	1	0.070	94 (46.3)	46 (46.0)	0.01	1	0.960
No	163 (53.8)	132 (60.3)	31 (36.9)				95 (58.6)	68 (48.2)				109 (53.7)	54 (54.0)			

IQR, Interquartile range; df, degrees of freedom.

Onset	Course	End State	AESOP (all) (n=279)	AESOP ^a (n=200)	AESOP ^b (n=126)	a ^c (n=228)	b (n=202)	c1 n	c2 n
acute	undulating	good	30%	22%	15%	25%	49%†	39%	29%
insidious	undulating	good	35%	36%	35%	10%	-	21%	23%
acute	continuous (simple)	good	1%	1%	1%	5%	2%	6%	5%
insidious	continuous (simple)	good	1%	1%	1%	10%	22%	8%	10%
acute	undulating	poor	6%	7%	8%	12%	9%	5%	5%
insidious	undulating	poor	5%	6%	6%	5%	-	3%	4%
acute	continuous (simple)	poor	7%	9%	10%	8%	1%	8%	9%
insidious	continuous (simple)	poor	15%	19%	24%	24%	11%	11%	14%

Fig. 2. Frequency (%) of course types, schematized following (a) Bleuler (1978) (schizophrenia), (b) Ciompi (1980) (schizophrenia) and (c) Harrison *et al.* (2001) (c1 all psychoses; c2 schizophrenia). ^a Non-affective psychoses only.

^b Schizophrenia only. ^c Modestin *et al.* (2003) re-evaluated cases in Bleuler's study, using operationalized criteria based on current standards and DSM-IV and ICD-10 criteria, and found that the proportions of cases with undulating and continuous courses did not vary much from those reported by Bleuler (e.g. 58% with undulating course in original study *versus* 48–49% in re-evaluation).

Service use: hospital admissions

Only 39 cases (12% of 338 on whom information was available) were never admitted to hospital at any point, 61 (18%) were admitted at initial presentation only and 238 (70%) were admitted at least once during the follow-up. Including first presentation, the median number of admissions was 2 (IQR 1–4, maximum number of admissions 20), with a small number of cases having 10 or more admissions (21, 6%). Considered differently, the admission rate was

0.31 [95% confidence interval (CI) 0.29–0.33] per year of follow-up or approximately one admission every 3 years. The median length of admission was 48 days (IQR 27–89) (number in analysis 293), and the median proportion of the follow-up spent in hospital was 2.5% (IQR 0.7–8.0) or around 14 weeks over an average of 520 weeks (10 years) of follow-up (number in analysis 327). The rate and length of admission tended to be less for those with an affective disorder and for those in Nottingham; the length, but not rate, of admission tended to be less for women (Table 4). Furthermore,

Table 3. Markers of social course and outcome

	Diagnosis, <i>n</i> (%)						Sex, <i>n</i> (%)					Centre, <i>n</i> (%)				
	Overall, <i>n</i> (%)	Non-affective (<i>n</i> =277)	Affective (<i>n</i> =110)	<i>F, t, χ²</i>	<i>df</i>	<i>p</i>	Men (<i>n</i> =215)	Women (<i>n</i> =172)	<i>F, t, χ²</i>	<i>df</i>	<i>p</i>	London (<i>n</i> =230)	Nottingham (<i>n</i> =157)	<i>F, t, χ²</i>	<i>df</i>	<i>p</i>
Percentage of time employed ^a (<i>n</i> =290)																
>75%	34 (11.7)	16 (7.6)	18 (22.5)	16.10	2	<0.001	21 (12.8)	13 (10.3)	0.77	2	0.681	15 (7.9)	19 (18.8)	7.74	2	0.021
25–75%	48 (16.6)	31 (14.8)	17 (21.3)				25 (15.2)	23 (18.3)				34 (18.0)	14 (13.9)			
<25%	208 (71.7)	163 (77.6)	45 (56.3)				118 (72.0)	90 (71.4)				140 (74.0)	68 (67.3)			
Employed at follow-up (<i>n</i> =295)																
No	229 (77.6)	178 (84.0)	51 (61.5)	17.41	1	<0.001	130 (78.3)	99 (76.7)	0.10	1	0.748	153 (81.8)	76 (70.4)	5.17	1	0.023
Yes	66 (22.4)	34 (16.0)	32 (38.6)				36 (21.7)	30 (23.3)				34 (18.2)	32 (29.6)			
Main relationship status ^b (<i>n</i> =307)																
In relationship	89 (29.0)	51 (22.9)	38 (45.2)	14.83	1	<0.001	40 (23.1)	49 (36.6)	6.63	1	0.010	48 (24.0)	41 (38.3)	6.94	1	0.008
Not in relationship	218 (71.0)	172 (77.1)	46 (54.8)				133 (76.9)	85 (63.4)				152 (76.0)	66 (61.7)			
In relationship at follow-up (<i>n</i> =300)																
Yes	95 (31.7)	54 (25.2)	41 (47.7)	14.23	1	<0.001	43 (25.9)	52 (38.8)	5.70	1	0.017	54 (27.0)	41 (41.0)	6.04	1	0.014
No	205 (68.3)	160 (74.8)	45 (52.3)				123 (74.1)	82 (61.2)				146 (73.0)	59 (59.0)			

df, Degrees of freedom.

^a Of the 97 for whom it was not possible to estimate percentage of total follow-up employed, 65 (67%) had no information on employment during the follow-up, 19 (20%) had at least one period of not being employed, 12 (12%) had at least one period of being employed, and one (1%) had at least one period of not being employed and one period of being employed.

^b Of the 80 for whom it was not possible to determine main relationship status during the follow-up, 63 (79%) had no information on relationship status during the follow-up, seven (9%) had been in a relationship at some point, and 10 (13%) had been single at some point.

Table 4. Hospital admissions

	Diagnosis						Sex					Centre				
	Overall	Non-affective (n=277)	Affective (n=110)	F, t, χ^2	df	p	Men (n=215)	Women (n=172)	F, t, χ^2	df	p	London (n=230)	Nottingham (n=157)	F, t, χ^2	df	p
Admission (n=338), n (%)																
Never	39 (11.5)	28 (11.5)	11 (11.7)	0.12	1	0.942	21 (11.2)	18 (11.9)	0.04	1	0.980	25 (11.7)	14 (11.2)	11.42	1	0.003
At baseline	61 (18.1)	43 (17.6)	18 (19.2)				34 (18.2)	27 (17.9)				27 (12.7)	34 (27.2)			
At follow-up	238 (70.4)	173 (70.9)	65 (69.1)				132 (70.6)	106 (70.2)				161 (75.6)	77 (61.6)			
Rate of admissions (n=338)																
IRR	–	1.00	0.85	–	–	0.024	1.00	1.04	–	–	0.547	1.00	0.76	–	–	<0.001
95% CI	–	–	0.74–0.98				–	0.92–1.17				–	0.67–0.87			
Length of admissions (n=293)																
Median	48	52	39	2.45	–	0.014	51	40	3.35	–	0.001	50	37	2.59	–	0.010
IQR	27–89	28–94	22–70				30–104	21–72				32–89	19–87			
Compulsory (n=369), n (%)																
Never	115 (31.2)	79 (29.7)	36 (35.0)	0.95	1	0.329	58 (27.8)	57 (35.4)	2.39	1	0.122	59 (26.5)	56 (38.4)	5.82	1	0.016
Once or more	254 (68.8)	187 (70.3)	67 (65.0)				150 (72.2)	104 (64.6)				164 (73.5)	90 (61.6)			

IRR, Incidence rate ratio; CI, confidence interval; df, degrees of freedom.

254 (69%) were compulsorily admitted to hospital either at first presentation or at some point during the follow-up (number in analysis 369), with compulsory admissions being more common in London (Table 4).

Discussion

Our follow-up provides novel data on the long-term course and outcome of all psychoses in a large unselected sample of incident cases. We found notable heterogeneity in clinical course and outcome. Only a minority of cases experienced continuous symptoms, with no periods of sustained remission, and less than half of these were rated as experiencing severe or negative symptoms. By contrast, almost half had been free of clinically significant psychotic symptoms for the 2 years prior to follow-up. This mirrors the findings for hospital admissions: high rates and long periods of admissions for a minority and low rates and relatively short admissions for a majority. For social outcomes, the picture was reversed: poor outcomes for a majority and good (or better) outcomes for a minority. Interpretation of the proportions with good outcomes, however, should be considered alongside the high mortality rate we found in this sample (see also Saha *et al.* 2007).

Methodological issues

In general, long-term follow-up studies face the twin problems of selection and information bias arising from loss to follow-up and missing or inaccurate data respectively.

In an attempt to minimize attrition, we were exhaustive in our efforts to trace cases and to establish deaths and emigrations. We were able to determine the whereabouts or status of over 90% of the cohort. When we compared those with some information available on course and outcome for 8 years or more with those without, there was (with the exception of mode of onset) no strong evidence of systematic bias. This does not rule out selection bias, but it does suggest attrition is unlikely to have seriously affected our findings.

Perhaps more problematic is the potential for information bias. We made use of all possible sources of information to complete the Life Chart, and clinical ratings were made by consensus after careful consideration of all available information. The extent and quality of information we had for each case, however, inevitably varied. The impact of this is difficult to assess. When we compared course and outcome variables by source of information, there was evidence that those for whom we did not have reinterview data

experienced a shorter time to first remission and were less likely to have a continuous course of disorder (Supplementary Table S5). We were very careful to only make ratings of presence or absence of symptoms on the basis of clear and definite information and it may indeed be that those who we did not reinterview did have better clinical outcomes. However, it is also possible that this apparent difference stems from uneven availability of information. Patients do not always disclose symptoms to clinicians and clinicians do not always accurately record what patients say. Consequently, it is possible that periods of remission were overestimated for those who we were not able to reinterview. Furthermore, completeness of information was inevitably less for those we did not reinterview. This urges caution in interpreting our results. For example, we found that clinical course and outcome were better in the Nottingham sample; at the same time, cases in Nottingham were less likely to be reinterviewed. In addition, across all cases in our core analytic sample, completeness of data was patchy because of incomplete case records and limited recall over what was, on average, a 10-year period.

Long-term course and outcome of psychoses

As indicated from our review, there is a dearth of long-term follow-up studies of incident cases of all psychoses, and differences in both study methods and location mean comparisons must be tentative.

This noted, within the context of marked heterogeneity in clinical course and outcome, our estimate that around 23% of all cases (rising to around 30% for non-affective psychoses) experienced a continuous course is notably lower than that found in the WHO International Study of Schizophrenia (ISoS) (i.e. 33% for all psychoses at 15 years), the only other follow-up of an incidence cohort of all psychoses that reports on overall course that we are aware of (Harrison *et al.* 2001). In a more direct comparison, our estimate of the proportion with a continuous course for Nottingham (15%) is also lower than for the Nottingham centre in the ISoS (24%) (Harrison & Mason, 2007). As noted, the lower rate of reinterview in Nottingham may bias estimates towards a good outcome in our Nottingham sample, but this has to be set against the overall tendency for those with an acute onset (and therefore possibly better outcomes) to be lost to follow-up. We will further examine site differences in future publications.

Considered the other way around, 12% (9% for non-affective) of our sample recovered within 6 months of contact with services and did not have a further episode, 20% (14% for non-affective) never had an episode lasting more than 6 months, and around 50%

(40% for non-affective) had not experienced symptoms in the 2 years prior to follow-up. Because of differences in the assessment of course and recovery in previous studies, direct comparisons are difficult. For example, only two first-episode studies from Europe have reported on the proportion who, following remission of the first episode, remained symptom free; the reported proportions were in line with ours (12% in Wiersma *et al.* 1998; 7% in Möller *et al.* 2010). In the studies we reviewed, estimates of proportions recovered, variously defined, ranged from 20% (Ciompi, 1980) to 61% (Harrison & Mason, 2007), the higher estimates being from studies of incident cases of all psychoses (e.g. Harrison *et al.* 2001) and from studies that defined recovery cross-sectionally (i.e. did not require absence of symptoms for 2 or more years) (Thara *et al.* 1994). This noted, our finding that around 40% of those with a non-affective disorder were symptomatically recovered is very similar to what Robinson *et al.* (2004) found over a 5-year follow-up period in their study of 118 first-episode schizophrenia cases (47%) initially recruited to a study of the application of a medication algorithm in clinical practice. This is striking and, together with our findings, suggests that roughly half of those who develop a psychosis will eventually recover symptomatically, suggesting much previous outcome research in schizophrenia and psychosis has provided overly pessimistic views of clinical course and outcome. Insofar as diagnosis should provide information about prognosis, non-affective disorders do generally follow less favourable trajectories than affective disorders (Harrow *et al.* 2005), but there is still considerable variability within these diagnostic groups.

Perhaps unsurprisingly, our findings on hospital admissions mirror those on clinical course and outcome, that is a high number of admissions and long in-patient stays for a minority and infrequent and relatively short admissions for most. There are very few comparable data in previous studies. White *et al.* (2009) did find a similar polarization of service use, with most of their sample over a 10-year period having a small number of admissions and a minority (18%) having more than 10. We found that only 6% of our sample had more than 10 admissions.

By contrast, using employment and relationship status as markers, social outcomes were poor for a majority of cases. At follow-up, only 22% were employed (compared with between 49% and 67% in the areas from which cases were originally recruited). This is broadly in line with previous studies. White *et al.* (2009), for example, found that 48% of their sample of 109 first admission cases followed at 10 years had never worked and only 19% were employed at follow-up. In their 10-year follow-up of participants in the

Treatment and Intervention in Psychosis (TIPS) trial of early detection, Hegelstad *et al.* (2012) found that only 11% of the detection as usual group and 28% of the early detection group were in full-time employment. Comparing across contexts is of course problematic because employment levels are affected by local socio-economic factors. Nonetheless, other studies that have used different measures and markers similarly suggest generally poor social outcomes (Supplementary Table S1). Perhaps most notably, our findings suggest that poor social outcomes reflect a persistence of social exclusion evident at first presentation, with only small proportions of those out of work (or single) moving into employment (or a relationship) by the 10-year end-point (around 15%).

Conclusions

In the analyses presented here, we purposefully considered clinical and social markers of course and outcome separately. In doing so, a discrepancy was evident: symptom remission and recovery is more common than social (re)integration following a first episode of psychosis. This points to a significant challenge for mental health services: improving social outcomes. It does so, however, without obscuring the finding that sustained symptom remission is possible for many with a psychotic disorder, a positive finding that goes against the still common view that non-affective psychotic disorders, especially schizophrenia, are chronic and deteriorating. This finding has important clinical implications; several recent reports have pointed out that psychiatrists who hold an overly pessimistic view of the outcome of psychosis can transmit this view to their patients, thereby rendering it a self-fulfilling prophecy (UK Schizophrenia Commission; www.schizophreniacommission.org.uk; Zipursky *et al.* 2013). The focus of forthcoming analyses of AESOP-10 data will be to identify tractable predictors of both clinical and social outcomes that can be targeted to improve long-term trajectories of psychoses.

Supplementary material

For supplementary material accompanying this paper visit <http://dx.doi.org/10.1017/S0033291714000282>.

Acknowledgements

This work was supported by the UK Medical Research Council (Ref. G0500817) and the Department of Health through the National Institute for Health Research (NIHR) Specialist Biomedical Research Centre for Mental Health award to the South London and

Maudsley NHS Foundation Trust (SLaM) and the Institute of Psychiatry at King's College London.

Declaration of Interest

R. Murray has received honoraria from Janssen, Astra-Zeneca, Lilly, BMS and Roche, and is an editor of *Psychological Medicine*.

References

- Andreasen NC, Carpenter WT Jr., Kane JM, Lasser RA, Marder SR, Weinberger DR (2005). Remission in schizophrenia: proposed criteria and rationale for consensus. *American Journal of Psychiatry* **162**, 441–449.
- Bleuler M (1978). *The Schizophrenia Disorders: Long-Term Patient and Family Studies*. Yale University Press: New Haven and London.
- Burns T, Creed F, Fahy T, Thompson S, Tyrer P, White I (1999). Intensive versus standard case management for severe psychotic illness: a randomised trial. UK 700 Group. *Lancet* **353**, 2185–2189.
- Ciampi L (1980). Catamnestic long-term study on the course of life and aging of schizophrenics. *Schizophrenia Bulletin* **6**, 606–618.
- Cohen P, Cohen J (1984). The clinician's illusion. *Archives of General Psychiatry* **41**, 1178–1182.
- Craig TK, Garety P, Power P, Rahaman N, Colbert S, Fornells-Ambrojo M, Dunn G (2004). The Lambeth Early Onset (LEO) Team: randomised controlled trial of the effectiveness of specialised care for early psychosis. *British Medical Journal* **329**, 1067.
- Crumlish N, Whitty P, Clarke M, Browne S, Kamali M, Gervin M, McTigue O, Kinsella A, Waddington JL, Larkin C, O'Callaghan E (2009). Beyond the critical period: longitudinal study of 8-year outcome in first-episode non-affective psychosis. *British Journal of Psychiatry* **194**, 18–24.
- Gafoor R, Nitsch D, McCrone P, Craig TKJ, Garety PA, Power P, McGuire P (2010). Effect of early intervention on 5-year outcome in non-affective psychosis. *British Journal of Psychiatry* **196**, 372–376.
- Harris MG, Henry LP, Harrigan SM, Purcell R, Schwartz OS, Farrelly SE, Prosser AL, Jackson HJ, McGorry PD (2005). The relationship between duration of untreated psychosis and outcome: an eight-year prospective study. *Schizophrenia Research* **79**, 85–93.
- Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J, Dube KC, Ganev K, Giel R, an der Heiden W, Holmberg SK, Janca A, Lee PW, Leon CA, Malhotra S, Marsella AJ, Nakane Y, Sartorius N, Shen Y, Skoda C, Thara R, Tsirkin SJ, Varma VK, Walsh D, Wiersma D (2001). Recovery from psychotic illness: a 15- and 25-year international follow-up study. *British Journal of Psychiatry* **178**, 506–517.
- Harrison G, Mason P (2007). Nottingham, UK. In *Recovery from Schizophrenia: An International Perspective* (ed. K. Hopper, G. Harrison, A. Janca and N. Sartorius), pp. 177–188. Oxford University Press: Oxford.
- Harrow M, Grossman LS, Jobe TH, Herbener ES (2005). Do patients with schizophrenia ever show periods of recovery? A 15-year multi-follow-up study. *Schizophrenia Bulletin* **31**, 723–734.
- Hegarty JD, Baldessarini RJ, Tohen M, Wateraux C, Oepen G (1994). One hundred years of schizophrenia: a meta-analysis of the outcome literature. *American Journal of Psychiatry* **151**, 1409–1416.
- Hegelstad WT, Larsen TK, Auestad B, Evensen J, Haahr U, Joa I, Johannessen JO, Langeveld J, Melle I, Opjordsmoen S, Rossberg JI, Rund BR, Simonsen E, Sundet K, Vaglum P, Friis S, McGlashan T (2012). Long-term follow-up of the TIPS early detection in psychosis study: effects on 10-year outcome. *American Journal of Psychiatry* **169**, 374–380.
- Hill M, Crumlish N, Clarke M, Whitty P, Owens E, Renwick L, Browne S, Macklin EA, Kinsella A, Larkin C, Waddington JL, O'Callaghan E (2012). Prospective relationship of duration of untreated psychosis to psychopathology and functional outcome over 12 years. *Schizophrenia Research* **141**, 215–221.
- Jaaskelainen E, Miettunen J, Veijola J, McGrath JJ, Murray GK, Jones PB, Isohanni M (2008). Associations between early development and outcome in schizophrenia – a 35-year follow-up of the Northern Finland 1966 Birth Cohort. *Schizophrenia Research* **99**, 29–37.
- Kirkbride J, Fearon P, Morgan C, Dazzan P, Morgan K, Tarrant J, Lloyd T, Holloway J, Hutchinson G, Leff J, Mallett R, Harrison G, Murray R, Jones P (2006). Heterogeneity in incidence rates of schizophrenia and other psychotic syndromes: findings from the 3-center AESOP study. *Archives of General Psychiatry* **63**, 250–258.
- Kurihara T, Kato M, Reverger R, Tirta IG (2011). Seventeen-year clinical outcome of schizophrenia in Bali. *European Psychiatry* **26**, 333–338.
- Larsen TK, Melle I, Auestad B, Friis S, Haahr U, Johannessen JO, Opjordsmoen S, Rund BR, Simonsen E, Vaglum P, McGlashan T (2006). Early detection of first-episode psychosis: the effect on 1-year outcome. *Schizophrenia Bulletin* **32**, 758–764.
- Larsen TK, Melle I, Auestad B, Haahr U, Joa I, Johannessen JO, Opjordsmoen S, Rund BR, Rossberg JI, Simonsen E, Vaglum P, Friis S, McGlashan T (2011). Early detection of psychosis: positive effects on 5-year outcome. *Psychological Medicine* **41**, 1461–1469.
- Malla A, Norman R, Bechard-Evans L, Schmitz N, Manchanda R, Cassidy C (2008). Factors influencing relapse during a 2-year follow-up of first-episode psychosis in a specialized early intervention service. *Psychological Medicine* **38**, 1585–1593.
- Menezes NM, Arenovich T, Zipursky RB (2006). A systematic review of longitudinal outcome studies of first-episode psychosis. *Psychological Medicine* **36**, 1349–1362.
- Modestin J, Huber A, Satirli E, Malti T, Hell D (2003). Long-term course of schizophrenic illness: Bleuler's study reconsidered. *American Journal of Psychiatry* **160**, 2202–2208.
- Möller HJ, Jager M, Riedel M, Obermeier M, Strauss A, Bottlender R (2010). The Munich 15-year follow-up study

- (MUFUSSAD) on first-hospitalized patients with schizophrenic or affective disorders: comparison of psychopathological and psychosocial course and outcome and prediction of chronicity. *European Archives of Psychiatry and Clinical Neuroscience* **260**, 367–384.
- Morgan C, Dazzan P, Morgan K, Jones P, Harrison G, Leff J, Murray R, Fearon P** (2006). First episode psychosis and ethnicity: initial findings from the AESOP study. *World Psychiatry* **5**, 40–46.
- Morgan C, Kirkbride J, Hutchinson G, Craig T, Morgan K, Dazzan P, Boydell J, Doody G, Jones P, Murray R, Leff J, Fearon P** (2008). Cumulative social disadvantage, ethnicity and first-episode psychosis: a case-control study. *Psychological Medicine* **38**, 1701–1715.
- Nordentoft M, Ohlenschlaeger J, Thorup A, Petersen L, Jeppesen P, Bertelsen M** (2010). Deinstitutionalization revisited: a 5-year follow-up of a randomized clinical trial of hospital-based rehabilitation versus specialized assertive intervention (OPUS) versus standard treatment for patients with first-episode schizophrenia spectrum disorders. *Psychological Medicine* **40**, 1619–1626.
- Norman RM, Manchanda R, Windell D, Harricharan R, Northcott S, Hassall L** (2012). The role of treatment delay in predicting 5-year outcomes in an early intervention program. *Psychological Medicine* **42**, 223–233.
- Robinson DG, Woerner MG, McMeniman M, Mendelowitz A, Bilder RM** (2004). Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. *American Journal of Psychiatry* **161**, 473–479.
- Saha S, Chant D, McGrath J** (2007). A systematic review of mortality in schizophrenia: is the differential mortality gap widening over time? *Archives of General Psychiatry* **64**, 1123–1131.
- Sartorius N, Gulbinat W, Harrison G, Laska E, Siegel C** (1996). Long-term follow-up of schizophrenia in 16 countries. A description of the International Study of Schizophrenia conducted by the World Health Organization. *Social Psychiatry and Psychiatric Epidemiology* **31**, 249–258.
- Thara R, Henrietta M, Joseph A, Rajkumar S, Eaton WW** (1994). Ten-year course of schizophrenia – the Madras longitudinal study. *Acta Psychiatrica Scandinavica* **90**, 329–336.
- van Os J, Wright P, Murray R** (1997). Follow-up studies of schizophrenia I: Natural history and non-psychopathological predictors of outcome. *European Psychiatry* **12** (Suppl. 5), 327s–341s.
- White C, Stirling J, Hopkins R, Morris J, Montague L, Tantam D, Lewis S** (2009). Predictors of 10-year outcome of first-episode psychosis. *Psychological Medicine* **39**, 1447–1456.
- WHO** (1992). *Schedules for Clinical Assessment in Neuropsychiatry*. World Health Organization: Geneva.
- Wiersma D, Nienhuis FJ, Slooff CJ, Giel R** (1998). Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. *Schizophrenia Bulletin* **24**, 75–85.
- Zipursky RB, Reilly TJ, Murrat RM** (2013). The myth of schizophrenia as a progressive brain disease. *Schizophrenia Bulletin* **39**, 1363–1372.